Dr. Christopher J. Sayed, MD
Dermatology (Dermatology Physician)
101 Manning Dr, Department Of Internal Medicine
Chapel Hill, NC 27514
- Medicare participating
At a glance
- Medical school
- University of North Carolina at Chapel Hill School of Medicine (2009)
- Years since graduation
- 17
- In the NPI registry since
- 2009
- Medicare patients seen, 2024
- 135
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2009Medical school: University of North Carolina at Chapel Hill School of Medicine
- 2009Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
NC license 2012-02147
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Unc Hospitals Chapel Hill, NC
Medical groups
- University of North Carolina at Chapel Hill (2,052 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 135
- Services billed
- 714
- Patients’ average age
- 62
| Service | Times | Patients |
|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 142 | 22 |
| Established patient office or other outpatient visit, 30-39 minutes | 117 | 79 |
| Established patient office or other outpatient visit, 20-29 minutes | 48 | 39 |
| Destruction of precancer skin growth, 1 growth | 28 | 23 |
| Destruction of skin growth, 1-14 growths | 21 | 19 |
| Biopsy of related skin growth, first growth | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Cosentyx Unoready Pen (secukinumab) | 87 |
| Humira(Cf) Pen (adalimumab) Other prescribers in Chapel Hill, NC | 86 |
| Methotrexate (methotrexate sodium) Other prescribers in Chapel Hill, NC | 58 |
| Triamcinolone Acetonide Other prescribers in Chapel Hill, NC | 49 |
| Ertapenem (ertapenem sodium) | 49 |
| Doxycycline Hyclate Other prescribers in Chapel Hill, NC | 49 |
| Remicade (infliximab) | 47 |
| Prednisone Other prescribers in Chapel Hill, NC | 46 |
| Amoxicillin-Clavulanate Potass (amoxicillin/potassium clav) Other prescribers in Chapel Hill, NC | 43 |
| Clindamycin Hcl Other prescribers in Chapel Hill, NC | 37 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 84 payments worth $155,312 in total to this clinician.
| AbbVie Inc. | $111,977 |
|---|---|
| UCB, Inc. | $17,596 |
| UCB SA | $13,355 |
| Sanofi-aventis U.S. LLC | $5,322 |
| Incyte Corporation | $4,875 |
| UCB Biosciences Inc. | $2,000 |
| Novartis Pharmaceuticals Corporation | $113 |
| Regeneron Healthcare Solutions, Inc. | $73.50 |
| Compensation for services other than consulting (speaking, faculty) | $108,610 |
|---|---|
| Consulting Fee | $34,852 |
| Travel and Lodging | $10,556 |
| Food and Beverage | $1,221 |
| Education | $73.50 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| UCB SA May 30, 2025 | Consulting Fee Bimzelx · Immunology | $8,280 |
| AbbVie Inc. Oct 16, 2025 | Consulting Fee | $7,200 |
| UCB, Inc. Dec 18, 2025 | Compensation for services other than consulting (speaking, faculty) Bimzelx · Immunology | $6,000 |
| AbbVie Inc. Feb 26, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $5,600 |
| AbbVie Inc. Mar 4, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $5,600 |
| AbbVie Inc. Nov 13, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $5,600 |
| AbbVie Inc. Dec 23, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $5,600 |
| AbbVie Inc. Aug 6, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $5,600 |
| AbbVie Inc. Aug 6, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $5,600 |
| Sanofi-aventis U.S. LLC Jul 8, 2025 | Consulting Fee | $5,322 |
All 58 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. Dec 23, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $5,600 |
| UCB, Inc. Dec 18, 2025 | Compensation for services other than consulting (speaking, faculty) Bimzelx · Immunology | $6,000 |
| AbbVie Inc. Dec 4, 2025 | Travel and Lodging RINVOQ · IMMUNOLOGY · travel to PINEHURST, NC · in-kind | $1,019 |
| UCB, Inc. Dec 3, 2025 | Travel and Lodging Bimzelx · Immunology · travel to Charlotte, NC · in-kind | $986 |
| UCB SA Nov 28, 2025 | Consulting Fee Bimzelx · Immunology | $345 |
| AbbVie Inc. Nov 24, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $4,000 |
| AbbVie Inc. Nov 13, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $5,600 |
| AbbVie Inc. Nov 13, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $4,000 |
| AbbVie Inc. Nov 13, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $4,000 |
| AbbVie Inc. Nov 10, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $4,000 |
| UCB, Inc. Nov 6, 2025 | Compensation for services other than consulting (speaking, faculty) Bimzelx · Immunology | $2,070 |
| AbbVie Inc. Oct 22, 2025 | Travel and Lodging RINVOQ · IMMUNOLOGY · travel to VIRGINIA BEACH, VA · in-kind | $2,210 |
| AbbVie Inc. Oct 22, 2025 | Travel and Lodging RINVOQ · IMMUNOLOGY · travel to VIRGINIA BEACH, VA · in-kind | $138 |
| UCB, Inc. Oct 21, 2025 | Travel and Lodging Bimzelx · Immunology · travel to Charlotte, NC · in-kind | $15.00 |
| AbbVie Inc. Oct 16, 2025 | Consulting Fee | $7,200 |
| AbbVie Inc. Oct 16, 2025 | Travel and Lodging travel to HILLSBOROUGH, NC · in-kind | $36.40 |
| AbbVie Inc. Oct 16, 2025 | Travel and Lodging travel to HILLSBOROUGH, NC · in-kind | $32.00 |
| AbbVie Inc. Oct 10, 2025 | Travel and Lodging travel to NORTH CHICAGO, IL · in-kind | $415 |
| AbbVie Inc. Oct 10, 2025 | Travel and Lodging travel to NORTH CHICAGO, IL · in-kind | $370 |
| AbbVie Inc. Oct 10, 2025 | Travel and Lodging travel to NORTH CHICAGO, IL · in-kind | $40.15 |
| AbbVie Inc. Oct 6, 2025 | Compensation for services other than consulting (speaking, faculty) SKYRIZI · IMMUNOLOGY | $4,000 |
| UCB SA Oct 3, 2025 | Consulting Fee Bimzelx · Immunology | $1,380 |
| UCB SA Oct 3, 2025 | Consulting Fee Bimzelx · Immunology | $650 |
| AbbVie Inc. Oct 1, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $4,000 |
| Regeneron Healthcare Solutions, Inc. Sep 26, 2025 | Education DUPIXENT · IMMUNOLOGY AND INFLAMMATION · in-kind | $73.50 |
| AbbVie Inc. Sep 18, 2025 | Travel and Lodging SKYRIZI · IMMUNOLOGY · travel to DURHAM, NC · in-kind | $21.00 |
| AbbVie Inc. Aug 6, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $5,600 |
| AbbVie Inc. Aug 6, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $5,600 |
| UCB Biosciences Inc. Jul 21, 2025 | Consulting Fee Bimzelx · Immunology | $2,000 |
| AbbVie Inc. Jul 10, 2025 | Travel and Lodging RINVOQ · IMMUNOLOGY · travel to NEWPORT, NC · in-kind | $1,707 |
| AbbVie Inc. Jul 10, 2025 | Travel and Lodging RINVOQ · IMMUNOLOGY · travel to CINCINNATI, OH · in-kind | $529 |
| Sanofi-aventis U.S. LLC Jul 8, 2025 | Consulting Fee | $5,322 |
| Incyte Corporation Jun 30, 2025 | Consulting Fee | $3,750 |
| AbbVie Inc. Jun 25, 2025 | Compensation for services other than consulting (speaking, faculty) SKYRIZI · IMMUNOLOGY | $4,000 |
| Incyte Corporation Jun 24, 2025 | Consulting Fee | $1,125 |
| AbbVie Inc. Jun 13, 2025 | Travel and Lodging RINVOQ · IMMUNOLOGY · travel to CINCINNATI, OH · in-kind | $28.00 |
| AbbVie Inc. Jun 10, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $4,000 |
| AbbVie Inc. Jun 10, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $4,000 |
| AbbVie Inc. Jun 6, 2025 | Travel and Lodging RINVOQ · IMMUNOLOGY · travel to CARY, NC · in-kind | $52.50 |
| AbbVie Inc. Jun 6, 2025 | Travel and Lodging RINVOQ · IMMUNOLOGY · travel to CINCINNATI, OH · in-kind | $49.70 |
| UCB SA May 30, 2025 | Consulting Fee Bimzelx · Immunology | $8,280 |
| AbbVie Inc. May 27, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $4,000 |
| AbbVie Inc. May 22, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $4,000 |
| AbbVie Inc. May 20, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $4,000 |
| AbbVie Inc. May 16, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $4,000 |
| AbbVie Inc. May 15, 2025 | Travel and Lodging RINVOQ · IMMUNOLOGY · travel to CARY, NC · in-kind | $1,397 |
| AbbVie Inc. Apr 15, 2025 | Consulting Fee | $800 |
| UCB, Inc. Apr 8, 2025 | Compensation for services other than consulting (speaking, faculty) Bimzelx · Immunology | $5,000 |
| UCB, Inc. Apr 8, 2025 | Travel and Lodging Bimzelx · Immunology · travel to Raleigh, NC · in-kind | $35.00 |
| AbbVie Inc. Mar 4, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $5,600 |
| UCB, Inc. Mar 4, 2025 | Compensation for services other than consulting (speaking, faculty) Bimzelx · Immunology | $1,940 |
| AbbVie Inc. Mar 4, 2025 | Travel and Lodging RINVOQ · IMMUNOLOGY · travel to SANFORD, NC · in-kind | $699 |
| AbbVie Inc. Feb 26, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $5,600 |
| UCB SA Feb 7, 2025 | Consulting Fee Bimzelx · Immunology | $2,700 |
| AbbVie Inc. Jan 23, 2025 | Travel and Lodging RINVOQ · IMMUNOLOGY · travel to SANFORD, NC · in-kind | $776 |
| AbbVie Inc. Jan 17, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $4,000 |
| AbbVie Inc. Jan 9, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $4,000 |
| UCB, Inc. Jan 9, 2025 | Consulting Fee Bimzelx · Immunology | $1,300 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 3 companies. The companies reported $1,208,340 in research payments for these studies, mostly to the institutions running them.
- An open label prospective study of Anifrolumab for the treatment of hidradenitis suppurativa
AstraZeneca Pharmaceuticals LP - A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
UCB SA · Completed · NCT04901195 - A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa
Incyte Corporation - A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
Incyte Corporation - The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa.
Incyte Corporation - Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
Incyte Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.